Bedford, mass.-based Ocular Therapeutix launched Phase III human clinical studies of its drug-releasing optical plug in patients undergoing cataract surgery.
Ocular Therapeutix launches Phase III trial for eye plug
Avedro application needs more work, FDA says
Massachusetts ophthalmic devices maker Avedro has some issues to address before the company can move forward with an FDA New Drug Application for its light-based cross-linking product for treatment.
Unilife raises $60M through debt financing, shares soar
Lumicell adds another $600,000 in funding
Imaging systems maker Lumicell Diagnostics amended a previously closed $1 million funding round after landing another $560,000 in financing from 2 new investors, regulatory filings show.
Alimera raises $37.5M in private placement
Alimera Sciences (NSDQ:ALIM) raised $37.5 million in a recent funding round, planning on using the funds to support general corporate operations.
Medtronic acquires drug/device maker TYRX for $160M
Drug delivery tech maker GeNO files for IPO of up to $50M
Waltham, Mass.-based GeNO LLC is hoping to raise as much as $50 million through an initial public offering, with funds slated to further development and commercialization of the company’s GeNOsyl drug delivery technology.
M&A rumor mill: Ikaria looks for a $2B exit
New Jersey critical care devices maker Ikaria Inc. is rumored to be looking for an exit, hoping to claim at least $2 billion, according to unnamed sources.
Ikaria is owned by private equity and venture capital companies including Mountain Capital LLC, ARCH Venture Partners LP and Venrock Associates LP.
Alimera's Iluvien vision repair implant wins national insurance coverage in France
The French National Health Authority granted Alimera Sciences (NSDQ:ALIM) national insurance coverage for the Iluvien vision repair implant, the company said this week.
